Dear community,
The regulatory landscape in Germany is currently undergoing a significant transformation. A core element is the planned expansion of the New Psychoactive Substances Act (NpSG), which will substantially adjust the framework for research, scientific analysis, and the handling of innovative chemical substances. Policymakers have made the objective clear: prevent misuse while enabling legitimate scientific work [2].
The German government has explicitly confirmed that the constitutional principle of legal certainty remains in full effect. This means: no vague catch-all bans, no undefined analog chains, and no retroactive restrictions. Legitimate research remains permitted and predictable.
“Broader formulations [...] would contradict the constitutional requirement of legal certainty and open up endlessly many variants.” [1] [3]
The political directive is clear: yes to public health protection, no to restricting responsible research.
Timeline: Key milestones
- August 15, 2025: Submission of the draft law to the Federal Council [2]
- September 26, 2025: Federal Council deliberation; request for broader structure-based bans [3]
- October 2, 2025: hib communiqué; rejection of blanket analog prohibitions [1]
- October 8–9, 2025: Presentation of the sixth amendment ordinance [4]
- Q4 2025: Second reading in Parliament
- End of 2025: Publication in the Federal Law Gazette
- Q1 2026: Entry into force with approx. three-month transition period [2]
Transparency and background: decision on October 24, 2025
On October 24, 2025, following publication of updated NpSG documents, we temporarily paused all affected products and removed them from the shop. The trigger was an immediate compliance signal from our monitoring systems.
We identified the regulatory signals on October 10, 2025, conducted full analysis from October 15, 2025, and acted after internal alignment.
Original notice: Important Information on the NpSG (October 24, 2025)
The decision was correct, although communication could have been more proactive. We take that feedback seriously.
We have since strengthened our communication processes:
- structured communication phases for regulatory events
- no unannounced assortment changes
- continuous status updates
- clear support flows for research customers
Thank you for your trust and constructive feedback.
Transition phase and controlled distribution
Regular sales of affected substances remain paused. Distribution only occurs:
- with documentation
- after legitimacy verification
- and strictly within the legal transition framework
Currently available stock:
Production and quality: our partner laboratory
All mentioned substances are produced exclusively through a specialized partner laboratory. We define specifications, purity standards, and testing procedures, and run regular quality assurance workflows. This ensures reproducible results, documented purity, and reliable supply chains for legitimate research.
Economic impact
The regulatory change affects not only operations but also economics. The substances O-DSMT HCl, SR-17018 HCl and IC-26 HCl generated around 1,500 monthly orders on average. This activity funds a full-time team of three employees, including:
- full health insurance and social security contributions
- payroll taxes
- corporate taxes
The regulatory restriction eliminates a significant revenue segment that previously secured employment, tax revenue, and ongoing research supply. We state this transparently because it reflects the reality of a compliant, responsible business model.
Despite the challenge, we continue to plan and execute responsibly and strategically.
Discounts and returning customer codes
All remaining inventory has been reduced by 15% to support ongoing research work during the transition. This reduction applies to all customers.
Additionally, our 5% returning customer discount continues. This is normally provided via physical voucher cards. Since the last shipping cycle before the sudden temporary pause did not include voucher cards, eligible returning customers will receive a fair alternative:
If you placed an order but did not receive a voucher card, you can simply "generate" your personal discount code. The code equals the final segment of your order ID.
Example:
Order ID: c4e1f2b9-8d54-4af3-91f8-d261e0c8a122
Discount code: d261e0c8a122
This ensures that no existing customer is disadvantaged and everyone who would have received a voucher card still receives the same benefit. If you do not have your order ID at hand, our support team will gladly assist.
O-DSMT HCl
O-DSMT HCl is temporarily sold out.A one-time, controlled restock is planned during the transition period.
Outlook: Stability and scientific alignment
We will continue developing our portfolio responsibly, focusing on:
- legally secure substance categories
- scientific relevance
- verified purity and analytical compliance
- qualified supply chains
We are also evaluating additional legal substance classes and nature-based and analytical products. New items will only launch after full legal and quality validation.
We continue investing in:
- supply chain resilience
- expanded lab reports and CoAs
- harm-reduction and scientific education
- digital compliance workflows
- community feedback and research-driven iteration
Our objective remains a stable, compliant, and research-oriented environment.
Your Remicals.de team